Publikationen
Eine aktuelle Übersicht der wissenschaftlichen Publikationen findet sich auf PubMed
Highlights
Keller N, Bertram D, Hamer H, Doerfler A, Schwab S, Rothhammer V*, Tsaktanis T*. Hospital resource use and costs in autoimmune encephalitis: a single-center retrospective cohort study. Neurol Res Pract. 2026 Apr 17;8(1):26. *geteilte Letztautorenschaft
Tsaktanis T*, Beyer T*, Nirschl L, Rotaru AI, Engleitner T, Öllinger R, Zuber F, Peter A, Zissler J, Tschurl V, Linnerbauer M, Lößlein L, Vandrey O, Rad R, Korn T, Rothhammer V. Interferon-β and FTY720 ameliorate progressive CNS inflammation via SOCS1-associated astrocyte signaling. Sci Rep. 2026 Mar 25;16(1):9851. *geteilte Erstautorenschaft
Bettray C*, Tsaktanis T*, Mennecke A, Serrano GB, Lang S, Lücking H, Singer L, Gerner S, Rothhammer V, Dörfler A, Schmidt MA. Artificial Intelligence analysis of lesion dynamics and brain volume in patients with multiple sclerosis. Mult Scler Relat Disord. 2026 Apr; 108:107033. *geteilte Erstautorenschaft
Tsaktanis T, Rudtke L, Ammon L, Mestermann S, Rothhammer V, Lewczuk P, Maler JM, Kornhuber J, Oberstein TJ. Reduced serum AHR agonistic activity reflects amyloid dysregulation in AT1 subtypes of Alzheimer's disease. Alzheimers Res Ther. 2026 Feb 6;18(1):47.
Tsaktanis T, Gessner A, Pfeuffer S, Farrenkopf D, Naumann UJ, Fröhlich K, Sembill JA, Fromm MF, Schwab S, Rothhammer V, Kuramatsu JB, Mrochen A. Metabolomic and immunophenotypic signatures in cerebral amyloid angiopathy: a pilot study. Sci Rep. 2025 Dec 5;15(1):43262.
Tsaktanis T, Ammon L, Lößlein L, Peter A, Vandrey O, Naumann UJ, Behne M, Cook LJ, Levy M, Yeaman MR, Bennett JL, Rothhammer V; Guthy-Jackson Charitable Foundation CIRCLES Study Group. Serum Levels of Aryl Hydrocarbon Receptor Plasma Agonist Activity Are Reduced in Patients With NMOSD and Correlate With Disease Activity. Neurol Neuroimmunol Neuroinflamm. 2025 Sep;12(5):e200457.
Tsaktanis T, Linnerbauer M, Lößlein L, Farrenkopf D, Vandrey O, Peter A, Cirac A, Beyer T, Nirschl L, Grummel V, Mühlau M, Bussas M, Hemmer B, Quintana FJ, Rothhammer V. Regulation of the programmed cell death protein 1/programmed cell death ligand 1 axis in relapsing-remitting multiple sclerosis. Brain Commun. 2023 Jul 25;5(4): fcad206.
Tsaktanis T, Beyer T, Nirschl L, Linnerbauer M, Grummel V, Bussas M, Tjon E, Mühlau M, Korn T, Hemmer B, Quintana FJ, Rothhammer V. Aryl Hydrocarbon Receptor Plasma Agonist Activity Correlates With Disease Activity in Progressive MS. Neurol Neuroimmunol Neuroinflamm. 2020 Dec 24;8(2): e933.
